Dieleman JP - Search Results

1

Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression.

Dieleman JP, Sturkenboom MC, Wit FW, Jambroes M, Mulder JW, Ten Veen JH, Juttmann J, Stricker BH, Lange JM, Van Der Ende ME; AIDS Therapy Evaluation, The Netherlands Study Group (ATHENA). Dieleman JP, et al. J Infect Dis. 2002 May 1;185(9):1261-8. doi: 10.1086/340131. Epub 2002 Apr 16. J Infect Dis. 2002. PMID: 12001043

2

Acute respiratory failure associated with the human immunodeficiency virus (HIV) protease inhibitor indinavir in an HIV-infected patient.

Dieleman JP, in 't Veld B, Borleffs JC, Schreij G. Dieleman JP, et al. Clin Infect Dis. 1998 Apr;26(4):1012-3. doi: 10.1086/517639. Clin Infect Dis. 1998. PMID: 9564505 No abstract available.

3

[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].

Dieleman JP, Hillebrand-Haverkort ME, van der Ende ME, Sturkenboom MC, Lange JM, Stricker BH. Dieleman JP, et al. Ned Tijdschr Geneeskd. 1998 Dec 26;142(52):2856-60. Ned Tijdschr Geneeskd. 1998. PMID: 10065260 Dutch.

4

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients.

Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Dieleman JP, et al. AIDS. 1999 Mar 11;13(4):473-8. doi: 10.1097/00002030-199903110-00005. AIDS. 1999. PMID: 10197375

5

Substituting nevirapine for protease inhibitors because of intolerance.

Dieleman JP, Gyssens IC, Sturkenboom MJ, Niesters HG, van der Ende ME. Dieleman JP, et al. AIDS. 1999 Jul 30;13(11):1423-4. doi: 10.1097/00002030-199907300-00029. AIDS. 1999. PMID: 10449304 No abstract available.

6

A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy.

Burger DM, Hugen PW, Aarnoutse RE, Dieleman JP, Prins JM, van der Poll T, ten Veen JH, Mulder JW, Meenhorst PL, Blok WL, van der Meer JT, Reiss P, Lange JM. Burger DM, et al. Among authors: dieleman jp. J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):218-24. doi: 10.1097/00042560-200103010-00003. J Acquir Immune Defic Syndr. 2001. PMID: 11242194 Free article. Clinical Trial.

7

Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy.

Bijl M, Dieleman JP, Simoons M, van der Ende ME. Bijl M, et al. Among authors: dieleman jp. J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):318-20. doi: 10.1097/00126334-200107010-00018. J Acquir Immune Defic Syndr. 2001. PMID: 11464156 No abstract available.

8

Papillary necrosis associated with the HIV protease inhibitor indinavir.

Dieleman JP, van der Feltz M, Bangma CH, Stricker BH, van der Ende ME. Dieleman JP, et al. Infection. 2001 Aug;29(4):232-3. doi: 10.1007/s15010-001-1105-y. Infection. 2001. PMID: 11545487

9

Indinavir crystallization around the loop of Henle: experimental evidence.

Dieleman JP, Salahuddin S, Hsu YS, Burger DM, Gyssens IC, Sturkenboom MC, Stricker BH, Kok DJ. Dieleman JP, et al. J Acquir Immune Defic Syndr. 2001 Sep 1;28(1):9-13. doi: 10.1097/00042560-200109010-00002. J Acquir Immune Defic Syndr. 2001. PMID: 11579271

10

Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort.

Dieleman JP, Jambroes M, Gyssens IC, Sturkenboom MC, Stricker BH, Mulder WM, de Wolf F, Weverling GJ, Lange JM, Reiss P, Brinkman K; ATHENA Study Group. Dieleman JP, et al. AIDS. 2002 Mar 29;16(5):737-45. doi: 10.1097/00002030-200203290-00009. AIDS. 2002. PMID: 11964530

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

118 results

Search Page

Filters